Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second Cycle DCVAC/PCa in Localized Prostate Cancer
NCT02137746Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Dec 2013
- Primary completion
- Apr 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stapuldencel in prostate cancer (PCa), sponsored by SOTIO Biotech. Primary endpoint: Safety evaluation of the second cycle of DCVAC at 52 weeks. Started Dec 2013; status: completed.
02
Drugs
stapuldencel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02137746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137746.